L50.0 Insurance Policy Changes

ICD-10 L50.0 is officially defined as "Allergic urticaria." code L50.0 is referenced in 4 tracked payer policy changes from UnitedHealthcare, Excellus BlueCross BlueShield, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code L50.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

UnitedHealthcare · Effective Oct 1, 2026Medium impact
Xolair ® (Omalizumab)
UnitedHealthcare Community Plan of Indiana has revised its Xolair (omalizumab) policy effective October 1, 2026, clarifying that provider-administered subcutaneous injections are covered for chronic urticaria, IgE-mediated food allergy, moderate-to-severe persistent asthma, and nasal polyps, while self-administered injections fall under pharmacy benefits. The policy also explicitly identifies conditions where Xolair is NOT covered (seasonal/perennial allergic rhinitis, atopic dermatitis, acute bronchospasm, anaphylaxis). Indiana is now included in coverage (previous policy excluded it).
Excellus BlueCross BlueShield · Effective Jul 16, 2026Medium impact
Allergy Testing 2.01.10
Percutaneous, combined percutaneous and intracutaneous, intracutaneous, patch, photo patch, photo, inhalation bronchial challenge, ingestion challenge, and gammaglobulin IgE tests are medically appropriate in the diagnosis of the allergic patient, with allergen-specific IgE medically appropriate only under specified circumstances. Allergen-specific IgG when the criteria are not met, the leukocyte histamine release test, ophthalmic and direct nasal mucous membrane tests, peanut allergen-specific ELISA testing, and cytotoxicity, provocative, and Rebuck skin window tests are investigational, and allergy testing for treatment programs such as tolerance induction programs is investigational. The July 16, 2026 update was an annual review with the policy intent unchanged.
Aetna · Identified Oct 10, 2026Medium impact
Repository Corticotropin Injection (Acthar Gel and Purified Cortrophin Gel) (CPB 0762, reviewed 2026-10-08)
Aetna considers repository corticotropin injection (Acthar Gel only) medically necessary for infantile spasms in members less than 2 years of age, and considers all other indications experimental, investigational, unproven, or not medically necessary. Precertification of Acthar Gel or Purified Cortrophin Gel is required of all Aetna participating providers and members in applicable plan designs. Purified Cortrophin Gel is considered experimental, investigational, or unproven for infantile spasms because it is not FDA-approved, nor has a compendial use, for this indication, and use of Acthar Gel in combination with Purified Cortrophin Gel is considered experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Hair Analysis (CPB 0300, reviewed 2026-04-17)
Aetna considers chemical hair analysis experimental, investigational or unproven, except for diagnosis of suspected chronic arsenic poisoning, and considers hair analysis of brain-derived neurotrophic factor as a predictor of developing psychopathological symptoms in childhood experimental, investigational or unproven. Microscopic evaluation of hair structure (trichogram) may be medically necessary as part of the work-up of members with alopecia or abnormal-appearing or abnormally growing hair.

Watch L50.0

Get one email when a payer policy names L50.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code L50.0?

There are 4 tracked policy changes affecting code L50.0, including updates from UnitedHealthcare, Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code L50.0?

Payers that have issued tracked updates for code L50.0 include: UnitedHealthcare, Excellus BlueCross BlueShield, Aetna.

How do I get notified when code L50.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code L50.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code L50.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Xolair ® (Omalizumab)

Allergy Testing 2.01.10

Repository Corticotropin Injection (Acthar Gel and Purified Cortrophin Gel) (CPB 0762, reviewed 2026-10-08)

Hair Analysis (CPB 0300, reviewed 2026-04-17)

What insurance policy changes affect code L50.0?

Which payers have updated policy for code L50.0?

How do I get notified when code L50.0 policy changes?

Why do payers change policies for code L50.0?